Author

Michelle K. Skime

Mayo ClinicORCID 0000-0001-7863-3017Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Genetic & Genomic Medicine· 2 Neuroscience· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Approach:statistical model· 3 Research Focus:differential expression· 2 Assay:electronic health records· 1 Research Focus:GWAS / association mapping· 1 Assay:GWAS summary statistics· 1 Assay:metabolomics· 1

Frequent Co-Authors

Anthony J. BatzleriD· 2 shared Brandon J. CoombesiD· 2 shared Joanna M. BiernackaiD· 2 shared Mark A. FryeiD· 2 shared Richard M. WeinshilboumiD· 2 shared Ada Man‐Choi HoiD· 1 shared Ahmed AhmediD· 1 shared Ahmed T. AhmediD· 1 shared

Activity by Year

2021-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 28 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersGenetic & Genomic Medicine

Anthony J. BatzlerORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Genetic & Genomic MedicinemedRxivPreprintSep 20, 2024

Genetic liability to insomnia and substance use disorders in patients with bipolar disorder

Lindsay Melhuish Beaupre, Brandon J. Coombes, Anthony J. Batzler…·Joanna M. Biernacka

The paper examines the association between insomnia genetic liability and substance use disorders in bipolar disorder patients using polygenic risk scores and electronic health records.

DOI 10.1101/2024.09.20.24314063

humanelectronic health records

𝕏 PostBluesky

Genetic & Genomic MedicineNeuropsychopharmacologyPeer-reviewedJul 23, 2021

Genetic Contributions to Alcohol Use Disorder Treatment Outcomes: A Genome-wide Pharmacogenomics Study

Joanna M. Biernacka, Brandon J. Coombes, Anthony J. Batzler…·Victor M. Karpyak

This study identifies genetic variants associated with AUD treatment outcomes using pharmacogenomic analyses of naltrexone and acamprosate responses.

48 citationstop 3%

humanGWAS summary statistics

𝕏 PostBluesky

NeuroscienceTranslational PsychiatryPeer-reviewedMar 2, 2021

Alterations in Acylcarnitines, Amines, and Lipids Inform about Mechanism of Action of Citalopram/Escitalopram in Major Depression

Siamak MahmoudianDehkordi, Ahmed T. Ahmed, Sudeepa Bhattacharyya…·Rick Jansen

The paper uses targeted metabolomics to analyze changes in acylcarnitines, amines, and lipids in response to citalopram/escitalopram treatment in MDD patients, identifying metabolic correlates of treatment response.

95 citationstop 1%

humanmetabolomics

𝕏 PostBluesky